
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial InfarctionAward last edited on: 3/4/2019
Sponsored Program
SBIRAwarding Agency
NIH : NIATotal Award Amount
$2,225,316Award Phase
2Solicitation Topic Code
-----Principal Investigator
Constance M S JohnCompany Information
Phase I
Contract Number: 1R44AG054386-01A1Start Date: 8/15/2016 Completed: 1/31/2017
Phase I year
2016Phase I Amount
$224,734Public Health Relevance Statement:
PROJECT NARRATIVE The overall goal of this project is to develop a protein inhibitor of galectin-3, termed galectin-3C, as a biologic to prevent and treat harmful remodeling after myocardial infarction and, thereby, improve cardiac function and reduce mortality from subsequent heart failure. Myocardial infarction is the most common cause of cardiac morbidity and mortality in the western world. The annual incidence in the United States is 610,000 new attacks and 325,000 recurrent attacks. Because current standard practice of minimizing time from onset of myocardial infarction to re-opening of the blocked artery has greatly reduced the incidence of death from acute myocardial infarction, heart failure subsequent to myocardial infarction has become the main mortality associated with coronary events.
Project Terms:
Achievement; Acute; Acute myocardial infarction; Adverse effects; Anesthetics; Angiotensin II Receptor; Angiotensin Receptor; Angiotensin-Converting Enzyme Inhibitors; Animal Model; Animals; Arteries; base; Cancer Patient; Cardiac; Cessation of life; chemotherapy; Cicatrix; Cleaved cell; clinical application; Collagen; Collagen Fiber; Connective Tissue; Continuous Infusion; Coronary; Coronary artery; cost; crosslink; cytokine; Deposition; Development; dosage; Drug Controls; drug development; Drug Kinetics; Elasticity; elastomeric; European Union; Event; experience; Extracellular Matrix; Fibroblasts; Fibrosis; Formulation; Functional disorder; Galactose Binding Lectin; Galectin 3; Goals; Growth; Health; Heart; Heart failure; heart function; hemodynamics; Human; Immune; Implant; improved; in vivo; Incidence; Infarction; Infection; Inflammatory; Infusion procedures; inhibitor/antagonist; Injury; Interleukin-1; Interleukin-13; interstitial; Investigational New Drug Application; Ischemia; Lead; Lectin; Left; Left Ventricular Ejection Fraction; Ligation; Losartan; Malignant neoplasm of prostate; Measurement; Mediator of activation protein; Medical; Methods; Mineralocorticoid Receptor; Miniature Swine; Modeling; Morbidity - disease rate; mortality; Myocardial Infarction; Myocardium; Myofibroblast; novel; novel therapeutics; Organ; Patients; Pharmaceutical Preparations; Phase; Physiological; Platelet-Derived Growth Factor; Positioning Attribute; pre-clinical; preclinical study; prevent; Prevention; Process; Procollagen; Production; Prognostic Marker; Property; Prostate-Specific Antigen; protein structure; Proteins; Pump; Rattus; Recurrence; Reperfusion Injury; Reperfusion Therapy; response; response to injury; Risk; Rodent; Serum; Small Business Innovation Research Grant; Testing; Therapeutic; Therapeutic Agents; Time; TNF gene; Toxicology; United States; Ventricular; Ventricular End-Systolic Volumes; Ventricular Function; Western World
Phase II
Contract Number: 4R44AG054386-02Start Date: 00/00/00 Completed: 00/00/00
Phase II year
2017(last award dollars: 2018)
Phase II Amount
$2,000,582Public Health Relevance Statement:
The overall goal of this project is to develop a protein inhibitor of galectin-3, termed galectin-3C, as a biologic to prevent and treat harmful remodeling after myocardial infarction and, thereby, improve cardiac function and reduce mortality from subsequent heart failure. Myocardial infarction is the most common cause of cardiac morbidity and mortality in the western world. The annual incidence in the United States is 610,000 new attacks and 325,000 recurrent attacks. Because current standard practice of minimizing time from onset of myocardial infarction to re-opening of the blocked artery has greatly reduced the incidence of death from acute myocardial infarction, heart failure subsequent to myocardial infarction has become the main mortality associated with coronary events.
Project Terms:
Achievement; Acute; Acute myocardial infarction; Adverse effects; Anesthetics; Angiotensin II Receptor; Angiotensin Receptor; Animal Model; Animals; Arteries; base; Cancer Patient; Cardiac; Cessation of life; chemotherapy; Cicatrix; Cleaved cell; clinical application; Collagen; Collagen Fiber; Connective Tissue; Continuous Infusion; Coronary; Coronary artery; cost; crosslink; cytokine; Deposition; dosage; Drug Controls; drug development; Drug Kinetics; Drug Targeting; Elasticity; elastomeric; Enzyme Inhibitor Drugs; European Union; Event; experience; Extracellular Matrix; Fibroblasts; Fibrosis; Formulation; Functional disorder; Galactose Binding Lectin; Galectin 3; Goals; Growth Factor; Health; Heart; Heart failure; heart function; hemodynamics; Human; Immune; Implant; improved; in vivo; Incidence; Infarction; Infection; Inflammatory; inhibitor/antagonist; Injury; Interleukin-13; interstitial; Intravenous; Intravenous infusion procedures; Investigational New Drug Application; Ischemia; Lead; Lectin; Left; Left Ventricular Ejection Fraction; Ligation; Losartan; Malignant neoplasm of prostate; Measurement; Mediator of activation protein; Medical; Methods; Mineralocorticoid Receptor; Miniature Swine; Modeling; Morbidity - disease rate; mortality; Myocardial Infarction; Myocardium; Myofibroblast; novel; novel therapeutics; Organ; Patients; Peptidyl-Dipeptidase A; Pharmaceutical Preparations; Phase; Physiological; Platelet-Derived Growth Factor; Positioning Attribute; preclinical development; preclinical study; prevent; Prevention; Process; Procollagen; Production; Prognostic Marker; Property; Prostate-Specific Antigen; Proteins; Pump; Rattus; Recurrence; Reperfusion Injury; Reperfusion Therapy; response; response to injury; Risk; Rodent; Serum; Small Business Innovation Research Grant; Structure; Testing; Therapeutic; Therapeutic Agents; Time; TNF gene; Toxicology; United States; Ventricular; Ventricular End-Systolic Volumes; Ventricular Function; Western World